Insulin-degrading enzyme

IDE Water Technologies Welcomes Juan Pablo Negroni as Country Manager, Chile

Retrieved on: 
Tuesday, May 25, 2021
Engineering, Chemicals, Plastics, Other Manufacturing, Manufacturing, Insulin-degrading enzyme, IDE, IDE, Integrated development environment, Engineering, Chemicals, Plastics, Other Manufacturing, Manufacturing, Insulin-degrading enzyme, IDE, IDE, Integrated development environment

IDE Water Technologies , a world leader in water treatment solutions, announces the appointment of Juan Pablo Negroni to County Manager for Chile.

Key Points: 
  • IDE Water Technologies , a world leader in water treatment solutions, announces the appointment of Juan Pablo Negroni to County Manager for Chile.
  • The IDE team in Chile welcomes the business acumen, technical knowledge and commercial insight he brings to the role and region.
  • We are thrilled to have Juan join our IDE team in Chile and we are excited about the extensive experience he brings in the water treatment, engineering and project management space, said Alon Tavor, CEO, IDE Water Technologies.
  • I am eager to join IDEs notoriously innovative team and to support continued growth for IDE in Chile, said Juan Pablo Negroni, Country Manager, Chile, IDE Water Technologies.

Peer-Reviewed Journal Publishes PrecivityAD™ Blood Test Research, Confirming Its Role in Assisting Clinicians in Alzheimer’s Diagnosis

Retrieved on: 
Wednesday, May 5, 2021
Medical devices, Health, General Health, Research, Science, Biotechnology, Branches of biology, Amyloidosis, Neuroscience, Biology, Alzheimer's disease, XE-class submarine, Amyloid-beta precursor protein, Insulin-degrading enzyme

\xe2\x80\x9cThis first publication in a peer-reviewed format is an important milestone and one we\xe2\x80\x99re proud to achieve.

Key Points: 
  • \xe2\x80\x9cThis first publication in a peer-reviewed format is an important milestone and one we\xe2\x80\x99re proud to achieve.
  • Even with the heterogeneity of samples, we found the test reliably detected brain amyloid \xe2\x80\x94 this speaks to the test\xe2\x80\x99s robustness.\xe2\x80\x9d\nPrecivityAD\xe2\x84\xa2 is the first widely accessible blood test to help physicians with diagnosing Alzheimer\xe2\x80\x99s disease.
  • It focuses its therapeutic discovery efforts around mechanism-based approaches to prevent or stop the progression of human neurological disorders.
  • Its lead commercial product, PrecivityAD\xe2\x84\xa2, is a mass spectrometry-based test that measures in blood multiple analytes including A\xce\xb242, A\xce\xb240, and apolipoprotein E isoforms.

Therapeutic Solutions International Reports Therapeutic Efficacy of StemVacs Derived Exosomes in Regression of Glioma

Retrieved on: 
Monday, February 1, 2021
Vesicles, Branches of biology, Exosome, Insulin-degrading enzyme

OCEANSIDE, Calif., Feb. 1, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), reported today new data demonstrating regression of an animal model of glioma using exosomes isolated from the Company's cellular immunotherapy product StemVacs.

Key Points: 
  • OCEANSIDE, Calif., Feb. 1, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), reported today new data demonstrating regression of an animal model of glioma using exosomes isolated from the Company's cellular immunotherapy product StemVacs.
  • Exosomes are cell derived nanoparticles which have been demonstrated to transmit biological information between cells.
  • Dr. Thomas Ichim, Board Member of the Company, published 16 years ago that exosomes from cancer are capable of suppressing immunity1.
  • "By leveraging our scientific colleagues and finding that StemVacs exosomes are effective in glioma, we are evaluating the possibility of applying for another Investigational New Drug application using exosomes."

Global Exosomes Pipeline Insight Report 2020: Insights on 50+ Companies and 50+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Friday, October 9, 2020
Health, Pharmaceutical, Vesicles, Exosome, Branches of biology, Pipeline, Insulin-degrading enzyme

The Exosomes - Pipeline Insight, 2020 report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Exosomes pipeline landscape.

Key Points: 
  • The Exosomes - Pipeline Insight, 2020 report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Exosomes pipeline landscape.
  • This segment of the Exosomes report encloses its detailed analysis of various drugs in the different stages of clinical development, including phase II, I, preclinical and Discovery.
  • This segment of the report provides insights about the different Exosomes based drugs segregated based on the following parameters that define the scope of the report, such as:
    There are approx.
  • Exosomes pipeline report provides the rapeutic assessment of the pipeline drugs by the Route of Administration.

Pulse Biosciences Announces FDA IDE Approval and Initiation of Sebaceous Hyperplasia Study

Retrieved on: 
Thursday, October 1, 2020
Medical devices, FDA, Health, Other Health, Pharmaceutical, Biotechnology, Human sexuality, Branches of biology, Biology, Investigational device exemption, Pharmaceutical industry, IDE, Food and Drug Administration, Sebaceous gland, Erotic electrostimulation, Hyperplasia, Insulin-degrading enzyme, Sebaceous Hyperplasia, Pulse Biosciences®

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation (NPS) technology, today announced FDA Investigational Device Exemption (IDE) approval and initiation of a pivotal study to evaluate the treatment of sebaceous hyperplasia (SH) lesions using the CellFX System.

Key Points: 
  • Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation (NPS) technology, today announced FDA Investigational Device Exemption (IDE) approval and initiation of a pivotal study to evaluate the treatment of sebaceous hyperplasia (SH) lesions using the CellFX System.
  • Following IDE approval, several patients have been enrolled, with the first patient procedure completed on September 28, 2020.
  • We are pleased to have received FDA IDE approval and to have begun this important SH comparative study slightly ahead of the fourth quarter start we had previously communicated.
  • Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

Cerapedics Announces FDA approval of an IDE supplement

Retrieved on: 
Wednesday, July 22, 2020
Insulin-degrading enzyme, IDE, Graft, Bone grafting

"We are pleased to announce FDA approval of an IDE supplement resulting in a reduction of the total number of patients required to be enrolled in our IDE study for P15-L cell-binding peptide technology in the TLIF application," said Jeffrey Marx, Ph.D., President and Chief Operating Officer of Cerapedics.

Key Points: 
  • "We are pleased to announce FDA approval of an IDE supplement resulting in a reduction of the total number of patients required to be enrolled in our IDE study for P15-L cell-binding peptide technology in the TLIF application," said Jeffrey Marx, Ph.D., President and Chief Operating Officer of Cerapedics.
  • The prospective, single-blinded, multi-center, randomized, non-inferiority pivotal IDE study will evaluate the safety and efficacy of P-15L Bone Graft compared to the use of an autologous bone graft when applied in TLIF surgery.
  • "The reduction in requirement will help us significantly reduce the enrollment period of the IDE Study and lead to an earlier PMA submission," said Glen Kashuba, Chief Executive Officer of Cerapedics.
  • Cerapedics is an ortho-biologics company focused on developing and commercializing its proprietary small peptide (P-15) technology platform.

Bioventus Makes $15 Million Equity Investment in CartiHeal with an Agreed Option Structure to Acquire Company Upon Milestone Achievements

Retrieved on: 
Thursday, July 16, 2020
Health, FDA, Medical devices, Surgery, Research, Science, Biotechnology, Health, Pharmaceutical industry, Investigational device exemption, IDE, Insulin-degrading enzyme, Integrated development environment, Food and Drug Administration, CartiHeal, the Agili-C implant IDE multinational pivotal study, Bioventus

The investment follows the recently completed enrollment and outcome of interim analysis in CartilHeals investigational device exemption (IDE) multinational pivotal study.

Key Points: 
  • The investment follows the recently completed enrollment and outcome of interim analysis in CartilHeals investigational device exemption (IDE) multinational pivotal study.
  • An additional $5 million can be secured by CartiHeal from Bioventus, if needed, for IDE study completion.
  • Bioventus made an initial $2.5 million investment in the Agili-C IDE study in January 2018, as part of a previous financing round.
  • Bioventus and CartiHeal have agreed on an option structure under which Bioventus will acquire the company shortly after FDA approval of the Agili-C implant.

Arvinas Appoints Wendy Dixon, Ph.D., to its Board of Directors

Retrieved on: 
Monday, June 29, 2020
Biotechnology, Pharmacology, Proteolysis targeting chimera, Insulin-degrading enzyme

NEW HAVEN, Conn., June 29, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Wendy Dixon, Ph.D., has joined its Board of Directors.

Key Points: 
  • NEW HAVEN, Conn., June 29, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Wendy Dixon, Ph.D., has joined its Board of Directors.
  • We are pleased to welcome Wendy to Arvinas Board of Directors and look forward to her valuable insight related to key functions such as marketing, strategic planning, and business development, said John Houston, Ph.D., President and Chief Executive Officer at Arvinas.
  • Wendy is joining Arvinas at a very exciting time as we continue to grow and accomplish milestones that bring us closer to our mission of offering therapeutic options to patients who have few or none.
  • Arvinas is leading the way in targeted protein degradation and has already proven the concept of their proprietary PROTAC platform, added Dr. Dixon.

GenScript Launches Beta Testing Program for New Precision Mutant Library Services

Retrieved on: 
Monday, April 8, 2019
Branches of biology, Biology, Genetics, Molecular genetics, Mutagenesis, Evolutionary biology, Saturation mutagenesis, Saturation, Mutant, Insulin-degrading enzyme

PISCATAWAY, N.J. and BOSTON, April 8, 2019 /PRNewswire/ -- GenScript , the world's leading gene synthesis provider, announced today at the PEGS Summit in Boston the launch of a public beta testing program for its new Precision Mutant Library Services for the drug development, industrial chemical and synthetic biology markets.

Key Points: 
  • PISCATAWAY, N.J. and BOSTON, April 8, 2019 /PRNewswire/ -- GenScript , the world's leading gene synthesis provider, announced today at the PEGS Summit in Boston the launch of a public beta testing program for its new Precision Mutant Library Services for the drug development, industrial chemical and synthetic biology markets.
  • GenScript's Precision Mutant Library Services involve construction of custom mutagenesis libraries using a patented semiconductor technology developed by CustomArray, Inc., which GenScript acquired in 2018.
  • GenScript's Precision Mutant Library Services include site-saturation mutagenesis, saturation scanning mutagenesis, or combinatorial mutagenesis libraries.
  • The new Precision Mutant Library Services offer specific benefits in the areas of therapeutic development and bioprocessing.

ProMIS Neurosciences Announces Fiscal Year 2018 Annual Results

Retrieved on: 
Friday, March 15, 2019
Branches of biology, Medical specialties, Proteins, Immunology, Alzheimer's disease, Immune system, Amyloid beta, Amyloidosis, Molecular neuroscience, Antibody, Amyloid, Insulin-degrading enzyme

In August 2018, we announced further evidence supporting potential for an improved safety profile in direct comparison to other amyloid beta-directed antibodies in clinical development.

Key Points: 
  • In August 2018, we announced further evidence supporting potential for an improved safety profile in direct comparison to other amyloid beta-directed antibodies in clinical development.
  • In June 2018, we announced the initiation of producer cell line development for PMN310, the first major step in the manufacturing process for therapeutic antibodies.
  • In October 2018, we announced identification of novel targets on misfolded,
    pathological forms of tau.
  • ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.